| Document |
Document Title |
|
WO/2024/094827A1 |
The present invention relates to protein ligands against Carbonic Anhydrase IX (CAIX) as target of biomedical relevance. In particular, the highly specific ligands may be able to exclusively interact with antigens expressed on the surfac...
|
|
WO/2024/096592A1 |
The present invention relates to an anti-mesothelin chimeric antigen receptor that specifically binds to mesothelin with increased affinity for methothelin. The anti-mesothelin chimeric antigen receptor according to an aspect exhibits sp...
|
|
WO/2024/097859A1 |
Provided are materials and methods for adjuvant and CD47 blockage cancer therapy. The adjuvant can be a nanoparticle with a cancer binding molecule and a SLAMF7 polypeptide attached. The binding of the nanoparticle to the cancer cell thr...
|
|
WO/2024/094131A1 |
Provided are a targeting molecule-cell complex capable of being used for the treatment and/or prevention of cancer, and a preparation method therefor. The targeting molecule-cell complex is a complex having formula (I) [X-A1-L-A2-D], whe...
|
|
WO/2024/098036A1 |
The subject matter described here relates to anti -PAG antibodies. The subject matter described here also provides a pharmaceutical composition of, or a kit for generating an anti-PAG antibody; a method of making an anti-PAG antibody; a ...
|
|
WO/2024/096522A1 |
The present invention relates to an antibody binding to CD22, and a bispecific antibody, a chimeric antigen receptor and an antibody-drug conjugate comprising same, and use thereof. According to one embodiment, an effective cancer treatm...
|
|
WO/2024/094660A1 |
The present invention relates to anti-CD38 antibodies comprising one or more mutations in the Fc region, and the use of such antibodies in the treatment of diseases in subjects, such as hematological malignancies.
|
|
WO/2024/097812A1 |
The present disclosure relates to methods of treating bladder cancer in a subject comprising intravesical administration of an effective amount of an anti-Trop-2 antibody drug conjugate (ADC) (e.g., sacituzumab govitecan) to the subject.
|
|
WO/2024/092354A1 |
Method for treating Ewing sarcoma in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of (E)-3-(2-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)m
ethyl)benzoyl)piperazin-1-yl)pyrimid...
|
|
WO/2024/093147A1 |
The present invention relates to an antibody specifically binding to the v5 exon of human CD44 or a fragment thereof. The present invention also relates to a chimeric antigen receptor molecule comprising the antibody or the fragment ther...
|
|
WO/2024/097228A1 |
The present disclosure provides compounds of Formula (I), Formula (II), and Formula (III), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, or prodrugs thereof. The provided compounds may be kinase (e....
|
|
WO/2024/094119A1 |
The present invention relates to a fusion protein, which comprises an anti-T cell surface molecular antibody, interleukin 2, and immunoglobulin Fc. The fusion protein is a heterodimer or a homodimer. The present invention further relates...
|
|
WO/2024/094817A1 |
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, ...
|
|
WO/2024/097758A1 |
Provided herein are methods of treating acute leukemia, such as acute myeloid leukemia (AML), in an individual, such as an individual having a mutation within the nucleophosmin 1 (NPM1) gene or a rearrangement within the lysine[K]-methyl...
|
|
WO/2024/097179A1 |
Disclosed herein are therapies comprising a CDK9 inhibitor of Formula (I), including therapies further comprising one or more additional pharmaceutically active agents, as treatments for cancer.
|
|
WO/2024/097911A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2024/094831A1 |
The present disclosure provides compositions comprising anti-CTLA-4 antibodies and related methods for treating cancer and other disorders responsive to anti-CTLA-4 antagonism.
|
|
WO/2024/097896A1 |
The present application provides compositions and methods for treating cancers, including advanced-stage metastatic cancer, using an anti-CTLA4 antibody in combination with pembrolizumab.
|
|
WO/2024/097307A1 |
The present disclosure features a method of preparing a population of payload-associated cell complexes (PACCs), as well as related methods of use thereof.
|
|
WO/2024/097391A1 |
4-Aminopyrrolo[2,I-f][1,2,4]triazine compounds of formula I for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4- aminopyrrolo[2,1-f][l,2,4]triazine compounds or ana...
|
|
WO/2024/096642A1 |
The present invention relates to a DNA aptamer for the diagnosis of colorectal cancer and, specifically, to a composition and a kit for the diagnosis of colorectal cancer, and a colorectal cancer-specific drug delivery composition, each ...
|
|
WO/2024/094819A1 |
The present invention provides compounds of Formula (Ia) or (Ib) and methods of use thereof.
|
|
WO/2024/097844A1 |
Provided herein are extra-cellular domain Mullerian hormone receptor type II (AMHR2-ED) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are AMHR2-ED binding molecules (e.g....
|
|
WO/2024/097905A1 |
Provided herein are adoptive cell therapy methods involving the administration of genetically engineered cells followed by an immunomodulatory agent maintenance therapy for treating disease and conditions, including certain plasma cell m...
|
|
WO/2024/097571A1 |
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhib...
|
|
WO/2024/094003A1 |
The present application relates to the field of biopharmaceuticals, and specifically relates to an antibody specifically binding to CCR8 or an antigen-binding fragment thereof, and a pharmaceutical composition and a kit comprising same. ...
|
|
WO/2024/097328A1 |
Methods of treating a cancer by administering to a subject an anti-GITR antibody in combination with at least one of a PD-1 inhibitor (e.g., an anti-PD-1 inhibitor), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody), or a CTLA-4 inhibitor...
|
|
WO/2024/095127A1 |
The present disclosure encompasses solid state forms of Tivozanib, in embodiments crystalline polymorphs of Tivozanib, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2024/092629A1 |
The present invention relates to a CAR-T cell with enhanced efficacy and lifetime, and use of nicotinamide mononucleotide in enhancing the efficacy and lifetime of the CAR-T cell. In addition, the present invention further relates to use...
|
|
WO/2024/097172A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2024/094004A1 |
The invention belongs to the technical field of cell immune engineering, and particularly relates to a fully human antigen binding fragment and single chain fragment variable targeting CD123, and a use thereof. The single chain fragment ...
|
|
WO/2024/092508A1 |
Provided are a method of a mesenchymal stem cell, e.g., a placenta-derived mesenchymal stem cell, for enhancing the treatment of a tumor by a CAR-T cell and/or treating a tumor in combination with a CAR-T cell, corresponding use, and a c...
|
|
WO/2024/097941A1 |
A method of treating malignancy in a subject in need thereof is provided. The method includes administering a therapeutically effective amount of a compound that increases the level of one or more of piR_017723, piR_23656, or piR_016745,...
|
|
WO/2024/095173A1 |
Disclosed herein are methods of treating cancers with combinations of a BCMAxCD3 bispecific antibody, an anti-CD3 antibody, and an immunomodulatory drug. Also provided are pharmaceutical compositions comprising the same and methods for g...
|
|
WO/2024/095012A1 |
The invention relates to a compound of formula (Ia) and related aspects.
|
|
WO/2024/097636A1 |
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα) for use in combination with additional therapeuti...
|
|
WO/2024/094112A1 |
The present invention relates to a selenium-containing substance for the treatment of cancer. Specifically, the present invention provides use of a seleno-amino acid for preparing a composition or a preparation. The composition or the pr...
|
|
WO/2024/095263A1 |
Conditioning protocols for use with anti-viral central memory CD8+ veto cells in haploidentical stem cell transplantation are provided. Accordingly, there is provided a method of treating a disease in a subject in need thereof, wherein t...
|
|
WO/2024/092614A1 |
Provided are a stable AST-3424 API product, a preparation method therefor, and storage thereof. The stable AST-3424 API product provided in the present invention is a solution of AST-3424 in ethanol, and the mass percentage of AST-3424 i...
|
|
WO/2024/097981A1 |
Disclosed are methods for the diagnosing and staging of cancers including, but not limited to multiple myeloma and treatment regimens incorporating said methods.
|
|
WO/2024/096753A1 |
The present invention provides compounds of Formula (la) or (lb): and methods of use thereof.
|
|
WO/2024/093882A1 |
Provided are a group CD24 binding proteins and uses thereof. Specifically provided is a group of antigen binding proteins, wherein cells expressing the antigen binding protein can have cytotoxicity and safety. Also provided is a use of t...
|
|
WO/2024/097918A1 |
This disclosure provides methods of treating cancers, such as lung cancer, esophageal cancer, renal cancer, and head and neck cancer, with NKG2D fusion proteins, NKG2D fusion proteins for use in methods of treating a subject having cance...
|
|
WO/2024/093056A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a KRAS_G12V mutant antigen, a fusion protein or conjugate comprising the TCR, a nucleic acid encoding the TCR and an engineered cell comprising same, and a ...
|
|
WO/2024/093681A1 |
Provided is use of infigratinib or a pharmaceutically acceptable salt thereof in preparing a medicament for treating and/or preventing gastric cancer or gastroesophageal junction adenocarcinoma, in particular, locally advanced or recurre...
|
|
WO/2024/094110A1 |
The present invention relates to a TM2 compound crystal form, a preparation method therefor, and a use thereof. The TM2 compound crystal form A is obtained by performing recrystallisation with at least one of ethyl acetate, absolute etha...
|
|
WO/2024/097876A1 |
A method of determining the likelihood that a subject with acute myeloid leukemia (AML) will respond to a treatment is provided. The method comprises detecting the levels of protein biomarkers in a biological sample obtained from a human...
|
|
WO/2024/092420A1 |
A preparation method for a compound VI, the compound VI having a fluorotertiary carbon chiral center and an azaquaternary carbon chiral center, making the compound difficult to synthesize. The preparation method provided by the present a...
|
|
WO/2024/094064A1 |
Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of lung cancer with a distant metastasis with a pyrimidinylaminobenzene, e.g., a compound of Formula (I).
|
|
WO/2024/094822A1 |
Provided are methods of clinical treatment of Richter's syndrome in human subjects using a bispecific antibody which binds to CD3 and CD20.
|
